Principal Health Economist
Emily joined BresMed in 2013 with a background in Biomedical Science.
During Emily’s career, she has led health economic modelling projects and health technology assessment submissions to the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC), and has developed and led projects involving early economic models and global economic models.
Emily has experience in a range of oncological and non-oncological indications. In the field of oncology, these indications include melanoma, multiple myeloma and non-small-cell lung cancer. Outside of oncology, Emily’s experience encompasses multiple sclerosis and several rare diseases.
Emily is also the Business Development Lead for the Health Economics Analysis team.